---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-062074"
form_type: "8-K"
ticker: "AURA"
cik: "0001501796"
company_name: "Aura Biosciences, Inc."
filed_at: "2023-11-09T23:59:59+00:00"
generated_at: "2026-06-08T06:37:06.078059+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Aura Biosciences raises $99M in public offering; Q3 net loss $18.5M

## Summary
- Closed underwritten public offering of 11M shares at $9.00/share, gross proceeds $99.0M; net proceeds ~$92.6M.
- Cash and securities $149.1M as of Sept 30, 2023; combined with offering proceeds, cash runway into H2 2026.
- Q3 2023 net loss $18.5M vs $15.9M YoY; R&D expenses $15.4M (up from $11.3M) driven by Phase 2/3 trial costs.
- Positive Phase 2 data for bel-sar in choroidal melanoma: 80% tumor control, 90% visual acuity preservation at 12 months.
- FDA agreed under SPA for Phase 3 CoMpass trial design; first patient dosing expected Q4 2023.

## SEC filing metadata
- accession: 0000950170-23-062074
- form_type: 8-K
- ticker: AURA
- cik: 0001501796
- company_name: Aura Biosciences, Inc.
- filed_at: 2023-11-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1501796/000095017023062074/0000950170-23-062074-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1501796/000095017023062074/aura-20231109.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-062074
- JSON: https://secwatch.observer/filing/0000950170-23-062074.json
- Plain text: https://secwatch.observer/filing/0000950170-23-062074.txt

## Key facts
- Earnings Releases
  Aura Biosciences, Inc. reported financial results for the third quarter ended September 30, 2023.
  - Period: the third quarter ended September 30, 2023
  - Result: reported results
  source text: On November 9, 2023, the Company issued a press release announcing its financial results for the quarter ended September 30, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1501796/000095017023062074/0000950170-23-062074-index.htm
- Material Agreements
  Aura Biosciences, Inc. entered into Underwriting Agreement with Leerink Partners LLC, Cowen and Company, LLC and Evercore Group L.L.C., as representatives of the several underwriters named therein valued at approximately $92.6 million (effective 2023-11-06).
  - Action: entry
  - Agreement: underwriting
  - Counterparty: Leerink Partners LLC, Cowen and Company, LLC and Evercore Group L.L.C., as representatives of the several underwriters named therein
  - Value: approximately $92.6 million
  - Effective: 2023-11-06
  source text: On November 6, 2023, Aura Biosciences, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Leerink Partners LLC, Cowen and Company, LLC and Evercore Group L.L.C., as representatives of the several underwriters named therein (the “Underwriters”), pursuant to which the Company agreed to issue and sell 11,000,000 shares of the Company’s common stock, par value $0.00001 per share (the “Common Stock”), to the Underwriters at a public offering price of $9.00 per share (the “Offering”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1501796/000095017023062074/0000950170-23-062074-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.